Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.

Challenges and opportunities for better lung cancer care for the elderly

A new editorial paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 15, Issue 17,

September 29, 2023

Shrinkage in the brain’s hippocampus area associated with cognitive decline

With the rise of new drugs that can target the amyloid-beta plaques in the brain that are an early sign of Alzheimer’s disease, new ways

November 16, 2023

Obesity-related cardiovascular deaths tripled in the last two decades, new study finds

Heart disease is killing fewer Americans overall, however, cardiovascular deaths where obesity was listed as a key contributing factor have tripled between 1999 and 2020,

September 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.